Dermata Therapeutics Future Growth

Future criteria checks 0/6

Dermata Therapeutics's earnings are forecast to decline at 19.3% per annum. EPS is expected to grow by 53.5% per annum.

Key information

-19.3%

Earnings growth rate

53.5%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	27 Mar 2024

Recent future growth updates

Recent updates

Dermata Therapeutics Q2 GAAP EPS of -$0.24

Aug 15

We're Hopeful That Dermata Therapeutics (NASDAQ:DRMA) Will Use Its Cash Wisely

Nov 22

Earnings and Revenue Growth Forecasts

NasdaqCM:DRMA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-15	N/A	N/A	1
12/31/2025	N/A	-15	N/A	N/A	1
12/31/2024	N/A	-12	N/A	N/A	1
12/31/2023	N/A	-8	-6	-6	N/A
9/30/2023	N/A	-7	-7	-7	N/A
6/30/2023	N/A	-8	-8	-8	N/A
3/31/2023	N/A	-9	-8	-8	N/A
12/31/2022	N/A	-10	-9	-9	N/A
9/30/2022	N/A	-10	-9	-9	N/A
6/30/2022	N/A	-12	-8	-8	N/A
3/31/2022	N/A	-11	-8	-8	N/A
12/31/2021	N/A	-10	-6	-6	N/A
9/30/2021	N/A	-8	-4	-4	N/A
6/30/2021	N/A	-5	-4	-4	N/A
3/31/2021	N/A	-4	-3	-3	N/A
12/31/2020	N/A	-3	-4	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRMA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DRMA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DRMA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if DRMA's revenue is forecast to grow faster than the US market.

High Growth Revenue: DRMA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DRMA's Return on Equity is forecast to be high in 3 years time

Dermata Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 96% to US$4.00

Recent updates

New major risk - Revenue and earnings growth

Dermata Therapeutics, Inc., Annual General Meeting, May 07, 2024

New major risk - Revenue and earnings growth

New major risk - Share price stability

Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols

New major risk - Share price stability

New major risk - Financial position

Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne

Dermata Therapeutics, Inc., Annual General Meeting, Aug 03, 2023

Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis

Price target decreased by 96% to US$4.00

Nasdaq Grants Dermata Therapeutics A 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Dermata Therapeutics, Inc. Announces Topline Results from Its Phase 2 Trial of Once-Weekly Topical Application of DMT310 for the Treatment of Moderate-To-Severe Rosacea

High number of new directors

Dermata Therapeutics Q2 GAAP EPS of -$0.24

Dermata Therapeutics, Inc. Receives Written Notice from the Listing Qualifications Department of Nasdaq for Compliance with the $1.00 Minimum Bid Price Requirement

Dermata Therapeutics, Inc., Annual General Meeting, Jul 11, 2022

High number of new directors

Dermata Therapeutics, Inc. Receives Correspondence from the U.S. Food and Drug Administration for Waiver Request for the Requirements to Complete a 90-Day Dermal Toxicity

Dermata Therapeutics, Inc. Submits Requests to the U.S. Food and Drug Administration for the Waiver of the Requirements to Complete A 90-Day Dermal Minipig Study and a Standard Dermal Pharmacokinetic Study

High number of new directors

We're Hopeful That Dermata Therapeutics (NASDAQ:DRMA) Will Use Its Cash Wisely

Chief Financial Officer Thomas Insley has left the company

Dermata Therapeutics, Inc. has completed an IPO in the amount of $17.999996 million.

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies